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Alzheimer’s Disease at Large
Alzheimer’s Disease (AD) is the most common form of dementia currently affecting over
50 million people worldwide, and over 5 million Americans (Alzheimer’s Association). One
third of Americans over the age of 85 are living with AD, and one in three seniors will die with
some form of dementia (Alzheimer’s Association). AD is a neurodegenerative disease
characterized by the loss of memory, thinking, ability to reason, and ability to care for one self.
Cognitive impairment is a hallmark sign of the disease which leads to the individual’s gradual
decline. Alzheimer’s disease kills more people every year than breast cancer, prostate cancer and
essential hypertension combined (Alzheimer’s Disease Facts and Statistics). A disease of this
caliber is not only devastating to the brain of the individual living with it, but the disease is also
costly. In 2018, the estimated cost of dementia and Alzheimer’s care in the U.S was $277 billion
dollars (Alzheimer’s Association). Not only have the healthcare costs of managing the disease
gone up, but the number of AD-associated deaths have increased by 89% between 2000 and
2014 (Alzheimers.Net).
Although the cause of AD is not fully understood yet, the disease process is associated
with amyloid plaques and neurofibrillary tangles in the brain. One of the protein fragments that’s
most commonly associated with Alzheimer’s is Beta-amyloid (ß-amyloid). β-amyloid is a sticky
protein fragment that disrupts communication between neurons (Alzheimer’s Association).
Recent evidence has shown that β-amyloid destroys synapses in the brain and causes the
formation of the plaques that lead to the death of brain cells (Kim et al 2013). β-amyloid is
largely responsible for widespread brain damage in AD causing loss of communication between
neurons and eventually cell death. The accumulation of ß-amyloid also induces the toxic form of
tau to accumulate in the brain which causes neurofibrillary tangles to form and neuronal death to
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take rise in AD (Deng et al. 2015). Tau is a protein that allows nutrients to be passed through the
brain, and the toxic form of this protein creates twisted fibers called neurofibrillary tangles
(Amyloid Plaques and Neurofibrillary Tangles). The formation of amyloid plaques and
neurofibrillary tangles can be exacerbated by a poor diet which causes AD to progress at a faster
rate (Hanson et. Al 2013).
A poor diet or a healthy diet can impact the body and also play a major role in brain
health (Hanson et al. 2013). With the treatment options for AD being both limited and expensive,
exploring the link between diet and AD is such a crucial endeavor to undertake in order to slow
the progression of the disease. AD is the one condition in the top 10 leading causes of death in
the U.S that can’t be cured or prevented. But recent scientific research has showed that it’s
possible to alter the rate at which β-amyloid plaques are cleared from the brain through dietary
substances (Alzheimers.net). The two natural dietary substances that will be investigated for the
purposes of this research are DHA omega-3 polyunsaturated fatty acids (DHA O3PUFAs), and
curcumin which have both been found to aid in clearing β-amyloid protein fragments from the
brain (Hoppe et al. 2013, Yan et al. 2019).
O3PUFAs are acids found in the body and in food, they are known to lower the amount
of triglycerides in the body (Docosahexaenoic Acid Healthline). Insofar as diet goes, O3PUFAs
are primarily found in fish (Docosahexaenoic Acid Healthline). Docosahexaenoic acid (DHA) is
the most common O3PUFA, and is found in in cold water fish more so than the other types of
O3PUFAs. DHA is also found in the human body as it is a structural component of the brain, and
the retina (Docosahexaenoic Acid Healthline). Humans primarily obtain DHA O3PUFAs from
their diet, and DHA has been found to help clear ß-Amyloid from the brain (Yan et al. 2019).
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Curcumin is a natural substance derived from turmeric, a plant which is native to India
where yellow curry is comes from. Curcumin is a powerful antioxidant, and also has antiinflammatory effects in the body. Research surrounding this plant-based substance is popular on
account of the fact that a large population of people that thrive on a plant-based diet often fail to
obtain adequate levels of DHA in the brain since they don’t eat fish (Wu et. Al 2015). It has been
found that curcumin enhances the synthesis of DHA which contributes to the clearance of ßamyloid plaques (Wu et. Al 2015).
This literature review seeks to contribute information on what is already known about the
neurological effects of DHA O3PUFAs and curcumin, and compare the two substances’ abilities
to clear ß-amyloid and alleviate the pathophysiological burden posed by ß-amyloid
accumulation. Learning about what natural dietary substances increase β-amyloid clearance has
possible implications for improving the conditions of the millions of people living with AD in
terms of increasing life expectancy, creating a healthier way of life, and coming closer to
eventually finding a cure.

History of Alzheimer’s
Alzheimer’s Disease was first identified by German psychiatrist, Dr. Alois Alzheimer, in
1906. Dr. Alzheimer. He described this disease after examining the brain of an older woman,
Auguste Deter, after she died of what was thought to have been an unusual mental illness.
Auguste Deter was only 50 when her increasing memory problems, paranoia, and aggression
became evident to her husband making admission to a psychiatric hospital necessary (The
History of Alzheimer’s Disease). The woman had suffered symptoms such as memory loss,
language problems, and behavior that was deemed unpredictable (Alzheimer’s Disease Fact
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Sheet). Before the neurological traits of AD were discovered, people displaying the signs and
symptoms of AD were treated as if they were mentally ill, and often institutionalized. When her
brain was thoroughly examined by Dr. Alzheimer following her death, abnormal clumps (now
identified as amyloid plaques) and bundles of tangled fiber (now identified as tau/neurofibrillary
tangles) were found in the deceased woman’s brain (Alzheimer’s Disease Fact Sheet). Plaques
and tangles are the hallmark features of AD on the anatomical level of the brain.
Since Dr. Alzheimer’s monumental discovery over one hundred years ago, many more
scientific inventions have aided in further discoveries regarding the causation and treatment of
AD creating milestones in AD understanding and treatment. Not too long after Dr. Alzheimer
described AD for the first time, the electron microscope was invented in 1931which allowed cell
magnification up to 1 million times which aided scientists in understanding neurons (History of
Alzheimer’s 2013). Decades after that groundbreaking invention, the National Institute on Aging
(NIA) was established and AD centers were funded by the NIA to establish a network for
research on the disease between the 1970s and 1980s (History of Alzheimer’s 2013). By the
early 1990s, the first AD drug became FDA approved, and today there are five medications
approved for use by the FDA (History of Alzheimer’s 2013). Awareness for AD also became
widespread when former President Ronald Reagan was diagnosed with it, and when the disease
became the 6th leading cause of death in U.S in 2010 (History of Alzheimer’s 2013). Despite the
innovations and discoveries that have been made throughout the last century, there is still much
that is unknown about this devastating disease, and much more to learn regarding its causation,
pathology, and how to cure it.
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Alzheimer’s Pathology
Dementia is an umbrella term for “diseases and conditions characterized by a decline in
memory, language, problem-solving, and other skills that affect a person’s ability to perform
everyday activities” (Alzheimer’s Association). AD is a form of dementia defined as the
“irreversible and incurable progressive neurodegenerative illness featuring cognitive and
functional deficits as well as loss of functional independence and behavioral changes” (Zvěřová
et al. 2019). Though there is no definitively known cause of AD, it’s speculated that a
combination of genetic, lifestyle, dietary, and environmental factors play a role in its
development.
Areas of the brain effected by AD are the hippocampus and the frontal lobe (National
Institute on Aging). The hippocampus is important for memory storage and memory formation.
As hippocampal cells degenerate as a result of AD, short-term memory begins to decline (The
Progression of Alzheimer’s). AD spreads through the outer layer of the brain known as the
cerebral cortex (The Progression of Alzheimer’s). Widespread neuronal death, then, causes the
brain tissues of a person with AD to shrink over time as the disease progresses, especially in the
frontal lobe (Kim et al 2013, National Institute on Aging). The frontal lobe is the brain region
largely responsible for language, executive functioning, and higher order thinking, and it is part
of the brain’s cerebral cortex (The Progression of Alzheimer’s). The spread of AD through the
cerebral cortex and to the frontal lobe is responsible for the worsening of judgement, emotional
outburst, and language impairment that are characteristics of AD in its later stages (The
Progression of Alzheimer’s). Both the hippocampus and the frontal lobe are affected by AD
when the plagues accumulate in these areas of the brain. AD spreads when plaques formed from
ß-amyloid accumulation and abnormal protein deposits accumulate in the brain which causes the
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disruption of synapses between neurons, and causes those neurons to die off (Kokawa et al.
2015).
A recent study speculates that AD specifically originates in a part of the brain known as
the “locus coeruleus” which is often the first place Alzheimer's-related pathology appears
(Mather and Harley 2016). The locus coeruleus (LC) is a vulnerable part of the brain struck by
AD, and may reveal damage decades before disease symptoms even become present. This part of
the brain is the first to show the build-up of the tau protein aggregate which contributes to the
tangles found in the brain that are characteristic of AD (Mather and Harley 2016). LC neurons
are associated with cognitive decline in the later stages of life (Mather and Harley 2016). The LC
is vulnerable to AD because of the long, unmyelinated axons of neurons coupled with its high
exposure to blood flow and proximity to the 4th ventricle of the brain that make it extremely
vulnerable to toxins (Mather and Harley 2016). LC neurons are affected by circulating toxicants
more than neurons in other brain regions due to the high exposure to blood circulation which
may expose the neurons to toxins that could cause AD. Norepineprine released by the LC helps
to maintain the blood–brain barrier (BBB) by protecting the neurons from inflammation and
neuronal damage (Mather and Harley 2016).

Beta Amyloid and the Amyloid Hypothesis
The phenomenon of ß-amyloid aggregation forms one of the most common disease
hypotheses for AD which is known as the “amyloid hypothesis”. The plaques associated with
AD are formed from a sticky protein aggregate known as ß-amyloid which disrupts
communication between neurons and initiates cell death thus causing cognitive decline. In AD,
brain cells that process, store and retrieve information degenerate and die. ß-amyloid
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accumulation destroys synapses and causes neuronal circuits to progressively dismantle in the
brain which leads to the death of brain cells (Hoppe et al. 2013, Kim et al. 2013). The imbalance
of β-amyloid production and ß-amyloid clearance ultimately leads to the aggregation, or the
clumping together of both ß-amyloid protein fragments to form plaques. This causes plaques
made from ß-amyloid peptides to accumulate in the brain thus disrupting neural synapses, and
causing cell death (Kokawa et al. 2015). The disruption of synapses as a result of ß-amyloid
accumulation is largely associated with the cognitive impairment aspect of AD.
The ß-amyloid peptides come in 42 different forms when the protein responsible for
cleaving or cutting ß-amyloid, the amyloid precursor protein, is split. The numbers of ß-amyloid
1-42 indicate isoforms, or protein variants, of different lengths that the peptide comes in
(Schmidt et al. 2009). ß-amyloid 1-40 are the most abundant ß-amyloid isoforms in the brain,
and ß-amyloid 40 and 42 are the isoforms found in AD (Schmidt et al. 2009). The ß-amyloid 40
and 42 peptides promote apoptosis or cell death more so than the other peptide isoforms (Lukiw
et al. 2005). The average clearance rate for both ß-amyloid 40 and ß-amyloid 42 is slower in
people with AD in comparison with healthy, normal brains without AD (Mawuenyega et al.
2010). ß-amyloid clearance is impaired by about 30% in patients that have AD (Mawuenyega et
al. 2010). Those with AD clear only 5.6% of ß-amyloid from their brains per hour versus the
7.6% per hour that is cleared by healthy controls without the disease (Mawuenyega et al. 2010).
Not only does ß-amyloid aggregation disrupt cell-to-cell communication, but it also
activates immune cells which triggers an inflammatory response causing the brain cells to be
destroyed (Beta-amyloid and the Amyloid Hypothesis). Although the exact causation of AD is
unknown, the accumulation of ß-amyloid is thought to be the primary cause of AD (Betaamyloid and the Amyloid Hypothesis). Clearing β-amyloid, therefore, could be important to
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healthy aging, and crucial in preventing AD from progressing at a faster rate (Mather and Harley
2016).
ß-amyloid, although it has negative cognitive effects, has been found to protect the brain
from microbial infection in mouse and worm models of AD (Kumar et al. 2016). It was
speculated by a recent study that the accumulation of ß-amyloid may take place as people age
because amyloid plaques accumulate in response to microbes present in the body as a defense
mechanism, and ß-amyloid has been found to kill off microbes (Kumar et al. 2016). This
suggests that microbial infection can be a triggering factor for the accumulation of ß-amyloid
(Kumar et al. 2016). When bacteria crosses the brain-to-blood barrier (BBB), the brain may be
responding to it by accumulating ß-amyloid to trap and kill bacteria. If the plaques aren’t cleared
away fast enough, they may lead to inflammation and tangles of tau protein to form, which
causes neurodegeneration and apoptosis (Kumar et al. 2016).

Amyloid Precursor Protein
The amyloid precursor protein (APP) is the protein responsible for producing β-amyloid.
APP is a type-1 transmembrane protein that causes the formation of β-amyloid protein fragments
through proteolysis (Priller et. Al. 2006). Though the exact physiological function of APP is still
unknown, it is thought to be a regulator of synapse formation and function, particularly synaptic
scaling and synaptic vesicle release (Priller et. Al. 2006, O’Brien and Wong 2011). APP passes
through a fatty membrane around the cell in order to extend from the inside of brain cells to the
outside (Beta-amyloid and the Amyloid Hypothesis). When APP is activated, the protein is cut
into separate, smaller protein fragments, such as ß-amyloid (Beta-amyloid and the Amyloid
Hypothesis). ß-amyloid is chemically stickier when APP is cut in comparison to the other protein
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fragments that are produced from the cleavage of APP (Beta-amyloid and the Amyloid
Hypothesis). ß-amyloid is speculated to be sticky because it undergoes a partial denaturation
which means that the protein loses its structure and ceases to function properly (Beta-amyloid
and the Amyloid Hypothesis).
When APP is cleaved by the α-secretase enzyme, ß-amyloid aggregates are not formed
which is the normal cleavage of APP (Patterson et al. 2008, O’Brien and Wong 2011). Soluble
APP-α peptide, which is generated from APP via the α-secretase pathway, decreases the
production of ß-amyloid peptides while supporting neural growth and stronger synaptic effects
(Lukiw et al. 2005). Though the ß-amyloid peptide that derives from APP is neurologically
destructive, the sAPPa peptide that comes from the a-secretase cleavage of APP enhances neural
synapses and promotes neurogenesis (Vanden Dries et al. 2017). sAPPa has been found to
decrease ß-amyloid generation (Deng et al. 2015; Vanden Dries et al. 2017).
When APP is cleaved by β-and γ-secretase enzymes, however, neurotoxic ß-amyloid
peptides get released which causes the accumulation of β-amyloid and the subsequent formation
of plaques (Patterson et al. 2008, O’Brien and Wong 2011). Proteolysis by ß-secretase or ysecretase is the abnormal cleavage of APP which is characteristic in AD. Mutations in the APP
gene tend to inhibit the ability for α-secretase cleavage which enables β-secretase and γ-secretase
cleavage (Patterson et al. 2008). Since large amounts of APP are metabolized into ß-amyloid in
the brain, ß-amyloid accumulation is partially due to alterations to the cleavage of APP that
result from AD risk factors (O’Brien and Wong 2011).
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Tau Protein and Neurofibrillary Tangles
Though the plaques formed by ß-amyloid are a prominent part of AD pathology,
neurofibrillary tangles made of tau protein are also a major component of the AD. The “tau”
hypothesis is thought by some people to be the main cause of AD. Tau protein forms the
microtubules that transport nutrients and crucial substances from one neuron to another. In AD,
tau proteins don’t stabilize microtubules properly. AD pathogenesis triggers the conversion of
tau from a normal to a toxic state through hyperphosphorylation causing the microtubles to
disintegrate (Castillo-Carranza et al. 2015). Hyperphosphorylation, the excessive addition of
phosphate molecules, causes tau proteins to break down and stick to each other instead of
supporting the microtubules (Beta-amyloid and Tau). Tau hyperphosphorylation occurs in
response to elevated ß-amyloid in the brain which causes tau aggregation and fibrillization into
neurofibrillary tangles (Hoppe et al 2013). Tau hyperphosphorylation causes the microtubule
structures to collapse which stops nutrients from going to brain and crossing the brain-to-blood
barrier (BBB) thus causing neurodegeneration and eventually cell death (Beta-amyloid and Tau).
Neurofibrillary tangles are twisted fibers found inside of neurons (Progression of
Alzheimer’s Disease). They are formed when tau proteins become misfolded and accumulate. In
AD, tau proteins form a C-shape, and once a tangle has been started, more tau proteins attached
to elongate the chain making a tangle (Amyloid Plaques and Neurofibrillary Tangles). The
molecule responsible for shaping tau proteins into a form that creates neurofibrillary tangles is
currently still unknown (Amyloid Plaques and Neurofibrillary Tangles). It has been found,
however, that the destruction of sAPPa, an APP fragment that enhances neural synapses and
promotes neurogenesis, helps to induce the formation of neurofibrillary tangles (Vanden Dries et
al. 2017).
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Interplay of ß-amyloid and Tau Protein
Though the two main hypotheses of AD, the amyloid hypothesis and the tau hypothesis,
suggest two different causes for which phenomenon is the main cause of AD pathogenesis, there
is evidence to suggest that there is a mechanistic relationship between ß-amyloid and tau
pathology. (Castillo-Carranza et al. 2015). Recent evidence suggests that ß-amyloid and tau do
not act in isolation of each other, but rather synergize in order to impair neural activity in AD
and drive neurons into the diseased state that indicates AD (Bloom 2014, Castillo-Carranza et al.
2015). It has been found that the signature, toxic properties of ß-amyloid require tau protein
(Bloom 2014). The accumulation of ß-amyloid is a major influence in tau pathology in that ßamyloid aggregation sets the stage for neurofibrillary tangles that contain the altered, toxic form
of tau protein to impair brain function (De Felice et al. 2008, Deng et al. 2015). An increase of ßamyloid levels in the brain induces tau hyperphosphorylation and thus propagates the rapid
spread of the toxic form of tau protein throughout the brain (De Felice et al. 2008, CastilloCarranza et al. 2015). The devastating neurological effects of ß-amyloid are also partially
controled by tau pathology since evidence suggests that tau mediates the level of toxicity
exhibited by ß-amyloid (Bloom 2014, Castillo-Carranza et al. 2015).

Acetylcholine Levels and AD
One of the harmful effects of AD induced by ß-amyloid accumulation is cholinergic
dysfunction (Minami et al. 1997). Acetylcholine levels are also crucial modulators of AD
pathology, specifically in regard to synapses, because cholinergic disruption is increased in
patients with AD (Minami et al. 1997). Acetylcholine is a neurotransmitter, or chemical
messenger released by neurons to convey information. Cholinergic function underlies a great
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deal of the short-term memory loss observed in AD (Liu et al. 2016). Acetylcholine plays a
crucial role in learning, memory and attention. Disruption of acetylcholine to the neocortex of
the brain impairs the learning of simple discrimination tasks, and disruption acetylcholine to
the hippocampus causes memory issues similar to anterograde amnesia in which one is unable to
recall the recent events while retaining long term memories (Easton et al. 2002). Acetylcholine
levels decrease in those experiencing memory impairment such as in AD largely because ßamyloid aggregation reduces acetylcholine levels in the hippocampus (Minami et al. 1997,
Hashimoto et al. 2005). Acetylcholine is created by the enzyme choline acetyltransferase (ChAT)
from the compounds choline and acetyl-coenzyme A (Puglielli et al. 2001). AD causes a
cholinergic deficiency as a result of reduced ChAT activity in the hippocampus which causes the
amount of acetylcholine in the hippocampus to also be reduced (Ishrat et al. 2009, Liu et al.
2016).
Acetylcholine deficiency in AD not only comes from a low amount of ChAT in the brain
needed to create acetylcholine, but also comes from the over activity of AChE in cleaving the
existing acetylcholine too rapidly (Chacón et al. 2003). When acetylcholine is released by
neurons, it cleaved by acetylcholinesterase (AChE) to terminate its effects in the synaptic cleft
(Chacón et al. 2003). The breakdown of acetylcholine via the over activity of AChE is
detrimental to the AD brain which is needed for synapses because AChE inactivates of
acetylcholine at synapses (Ahmed et al. 2009). Acetylcholine being cleaved too quickly by
AChE means that the neurotransmitter, acetylcholine, does not have time to exhibit its complete
effect (Chacón et al. 2003). ß-amyloid decreases acetylcholine levels in the brain and ß-amyloid
also increases AChE activity (García-Ayllón et al. 2008). AChE promotes the assembly of toxic
ß-amyloid peptides and also increases the neurotoxicity of the ß-amyloid along with inducing
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neuronal death (Chacón et al. 2003, García-Ayllón et al. 2008, Syamima et al. 2019). AChE can
be found in senile plaques in AD that are made from ß-amyloid demonstrating the enzyme’s role
in AD pathology (Chacón et al. 2003, Syamima et al. 2019).
Cholesterol also modulates the rate and mechanism by which acetylcholine receptors
draw acetylcholine into the cell or internalizes (Borroni and Barrantes 2011). Not only is ßamyloid production and aggregation modulated by cholesterol, but cholesterol is also necessary
in order for the homeostasis of acetylcholine receptor levels to be maintained (Borroni and
Barrantes 2011, Di Paolo and Kim 2011). Dysregulation of cholesterol metabolism can play a
potent role in the pathology of AD in relation to cholinergic degeneration because high levels of
cholesterol cause an increase in AChE activity which contributes to the cognitive impairment
seen in AD (Moreira et al. 2012, Moreira et al. 2014). Cholesterol homeostasis, therefore, is
important in acetylcholine level maintenance (Moreira et al. 2012, Moreira et al. 2014).
Preserving acetylcholine levels in AD is important because cholinergic neurons play an
indispensable role in memory function, and the progressive disruption of cholinergic function
seen in AD pathology underlies much the short-term memory loss observed in AD (Liu et al.
2016). Memory loss in AD correlates more so with synapse loss than with plaques or tangles
which is why improving the acetylcholine levels at the synapse is crucial (Calon et al. 2004).

Inflammation Caused by Oxidative Stress in AD
Oxidative stress is one of the pathological hallmarks of AD induced by ß-amyloid
aggregation. Free radicals are unstable atoms that damage cells which can cause illness and
accelerate aging and apoptosis (Reddy 2006). When oxygen molecules split into single atoms
with unpaired electrons, they become unstable, free atoms (hence “free radicals”) that try to bond
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to other molecules (Pham-Huy et al. 2008). Free radicals derived from oxygen are known
collectively as reactive oxygen species, and the accumulation of free radicals is known as
oxidative stress (Pham-Huy et al. 2008). ß-amyloid impacts the AD brain by inducing the
production of free radicals and increasing oxidative stress in AD which causes inflammation
(Reddy 2006).
As neurodegenerative diseases like AD progress, the brain it loses its ability to fight the
effects of free radicals, and undergoes oxidative stress as a result (Pham-Huy et al. 2008). ßamyloid entering the mitochondria is what leads to the development of excessive free radicals
and subsequent oxidative stress and inflammation (Reddy 2006). ß-amyloid inducing the
generation of free radicals is what causes the neuronal damage and loss of synaptic function
hallmark in AD (Reddy 2006). More free radicals cause more oxidative stress, which causes
more damage to cells thus contributing to the neurodegenerative pathology of AD (Reddy 2006,
Pham-Huy et al. 2008). Oxidative stress and inflammation also impacts the integrity of the BBB
because the BBB becomes more permeable during inflammation thus allowing more ß-amyloid
to get through (Pan et al. 2018).
The oxidation of lipids is known as lipid peroxidation, and it is the degradation of lipids
that results from the destructive process of oxidation (Pham-Huy et al. 2008). The production of
toxic ß-amyloid peptides is accelerated by lipid peroxidation (Pham-Huy et al. 2008). ß-amyloid
facilitating the generation of free radicals causes lipid peroxidation and increases the amount of
reactive oxidative species present (Hensley et al. 1994, Reddy 2006). This is because the
production of free radicals in excess alters the structures or cell membranes and lipids (PhamHuy et al. 2008). The body’s defense mechanism against oxidative stress is the production of
anti-oxidants which are substances in the body that prevent or slow the damage to cells caused
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by free radicals and reduce inflammatory responses (Reddy 2006, Pham-Huy et al. 2008). The
overwhelming amount of oxidative stress producing more free radicals than can be eliminated
with anti-oxidants poses a problem in the AD pathogenesis (Pham-Huy et al. 2008).
Oxidative stress also enhances the activity of AChE thus preventing adequate
acetylcholine synaptic levels and causing cholinergic dysfunction which leads to induces ßamyloid production (Minami et al. 1997, Melo et al. 2003, Ishrat et al. 2009). The hippocampus
and cortical regions of the brain are the areas primarily involved in cholinergic transmission
since they modulating memory processing and learning and these brain areas in particular are
also more prone to oxidative damage in the AD pathogenesis (Ishrat et al. 2009). Oxidative
damage to lipids progresses AD by disrupting the cell membranes of neurons, inactivating
enzymes such as AChE, and causing cells to die (Melo et al. 2003, Ishrat et al. 2009).

Role of the Brain-to Blood Barrier in AD
The brain-to-blood barrier (BBB) is a semipermeable border that separates the circulating
blood from the brain and extracellular fluid in the central nervous system (Daneman and Prat
2015). The BBB is comprised of a network of blood vessels that blocks harmful substances and
pathogens from going into the brain, while allowing essential nutrients to enter (Daneman and
Prat 2015). The BBB has endothelial cells are connected by tight junctions that that line blood
vessels in the central nervous system and prevent most molecules from passing between them
(Andreone et al. 2017). ß-amyloid and the toxic form of tau proteins, however, are able to cross
the barrier which is why the clearance of ß-amyloid and other toxins is indispensable to
maintaining brain health (Yan et al. 2019). The BBB becomes compromised when inflammation
from oxidative stress weakens the BBB by increasing its permeability to the destructive amyloid
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which causes neurodegeneration and cell apoptosis (Magaki et al. 2018). In AD, blood plasma
containing ß-amyloid enters the brain via the BBB and adheres to astrocytes which are the starshaped glial cells that regulate neuronal synapses and provide support for the neurons
(Hooijmans et al. 2007, Zipser et. al 2007). ß-amyloid adhering to the glial cells (astrocytes) that
provide structural support to the neurons weakens the BBB.
Though the specific relationship between cerebral capillaries and amyloid plaques is not
completely understood, recent evidence has suggested that plaques may result from leaky
capillaries that allow ß-amyloid into the BBB (Zipser et. al 2007). This suggests that vascular
damage plays a role in the pathogenesis of AD, specifically in the micro-vascular structure of the
BBB since the disease is aggravated by the gradual breakdown of the BBB due to ß-amyloid
(Zipser et. al 2007). The BBB may also be compromised by the accumulation of amyloid plaques
in the wall of arteries and capillaries which is known as cerebral amyloid angioplasty (CAA)
(Magaki et al. 2018). Cerebral amyloid angiopathy is another major hallmark often occurring in
AD pathology (Liu et al. 2013). About 85% of people with AD also have CAA which accounts
for the integrity of the BBB becoming weakened as a result of ß-amyloid in the blood vessels
(Magaki et al. 2018). The phenomenon of ß-amyloid being inside of blood vessels like capillaries
and arteries in AD makes a high percent of AD cases fall under the umbrella of vascular
dementia which is when the brain and cells undergoes neurodegenerative damage as a result of
issues with the BBB (Magaki et al. 2018). AD and CAA represent two sides of a single condition
which is cerebral amyloidosis caused by ß-amyloid (Yamada 2012). CAA is capable of
exacerbating BBB dysfunction related to AD which is why vascular dementia and AD often
occur together (Magaki et al. 2018). The BBB and its structural integrity becomes compromised
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when inflammation weakens the BBB by increasing its permeability to the destructive ß-amyloid
thus causing neurodegeneration and cell apoptosis (Magaki et al. 2018).
The primary receptors used for the transport of ß-amyloid peptides and tau protein across
the BBB are known as low-density lipoprotein receptor related protein-1 (LRP-1) (Deane et al.
2015, Yan et. al 2019). LRP-1 is responsible for bringing nutrients to the BBB, but since the
BBB is permeable to ß-amyloid and tau protein, those are also transported by LRP-1 (Deane et
al. 2015, Yan et. al 2019). The declination of LRP-1 levels in the brain as a part of aging
contributes to the imbalance of β-Amyloid that is characteristic of AD (Deane et al. 2015, Yan
et. al 2019). The BBB is dependent on LRP-1 to clear β-Amyloid from the brain, therefore,
greater LRP-1 production means that more β-Amyloid can be cleared by the brain-blood barrier
which helps to mediate the imbalance of β-Amyloid in the brain. (Yan et. al 2019).

Cholesterol and AD
Defects in cholesterol homeostasis in the adult brain are linked to AD in that ß-amyloid
production and clearance is regulated by cholesterol, and high cholesterol is neurotoxic (Yao and
Papadopoulos 2002, Di Paolo and Kim 2011). The human brain is the most cholesterol-rich
organ in the body containing 25–30% of the total body cholesterol (Di Paolo and Kim 2011).
Lipids control many aspects of the AD pathogenesis in that lipids, like cholesterol, control the
processing of amyloid precursor protein, the synaptotoxic signaling of both ß-amyloid formation
and tau pathology formation (Hashimoto et al. 2005). Because cholesterol plays an important
role in ß-amyloid formation, one of the physiological functions of APP is to control cholesterol
transport as well as homeostasis (Yao and Papadopoulos 2002).
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Low-density lipoprotein (LDL) cholesterol is the “bad” form of cholesterol which leads
to ß-amyloid accumulation (Yao and Papadopoulos 2002, Di Paolo and Kim 2011). High levels
of LDL cholesterol induce the processing of APP and increase APP cleaving ß-amyloid
eventually leading to the formation of ß-amyloid plaques (Yao and Papadopoulos 2002). High
levels of LDL cholesterol cause the LDL cholesterol to bind to the α-secretase site of APP thus
blocking the action of the enzyme which generates the toxic form of ß-amyloid (Yao and
Papadopoulos 2002). Low levels of LDL cholesterol, conversely, cause APP to be cleaved in a
way that does not generate ß-amyloid (Yao and Papadopoulos 2002). When there is a low
amount of LDL cholesterol, APP is cleaved by α-secretase which overrides the amount of toxic
ß-amyloid 40-42 peptides formed (Yao and Papadopoulos 2002). Changes in cholesterol
transport and homeostasis, therefore, lead to neurotoxicity medicated by ß-amyloid.
Hypercholesterolemia, or high LDL cholesterol in the blood, is a risk factor for AD and
vascular dementia because it impairs the integrity of the BBB and induces ß-amyloid
overproduction (Hooijmans et al. 2007). CAA, the phenomenon of ß-amyloid in the blood
vessels, is exacerbated by high cholesterol levels since the formation of ß-amyloid is modulated
by LDL cholesterol (Di Paolo and Kim 2011, Reed et al. 2014). An increase of cholesterol in the
cerebral vasculature causes vulnerable areas of the brain to experience hypoperfusion, or reduced
blood flow (Hooijmans et al. 2007). The removal of LDL cholesterol from the brain is important
because high levels of LDL cholesterol accelerate the formation of ß-amyloid plaques (Zuliani et
al. 2010, Di Paolo and Kim 2011).
High-density lipoprotein (HDL) cholesterol, on the other hand, is respectively known as
the “good” form of cholesterol, and it helps to remove LDL cholesterol from the blood Zuliani et
al. 2010, Di Paolo and Kim 2011). HDL cholesterol is also crucial for synapse generation,
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maturation, and symaptic plasticity in that it increases the number of synaptic vesicles which
have high cholesterol levels (Mauch et al. 2001, Zuliani et al. 2010, McGrowder et al. 2011).
HDL cholesterol is important to AD pathology because along with helping to remove LDL
cholesterol, it is also involved in helping to clear the ß-amyloid from the brain and even plays a
role in maintaining the integrity of the BBB (Ole and Lone 2000, Zuliani et al. 2010,
McGrowder et al. 2011).
The apolipoprotein E (ApoE) gene is the major cholesterol carrier that transports lipids
like cholesterol, supports injury repair in the brain, and is a genetic determinant of AD
pathogenesis (Liu et al. 2013, Devassy et al. 2016) While ApoE mainly regulates homeostasis by
acting as a lipid transporter in the brain, it also regulates ß-amyloid formation and aggregation
(Liu et al. 2013, Devassy et al. 2016). ApoE exists in three major isoforms which are ApoE ε2,
ApoE ε3, and ApoE ε4 (Devassy et al. 2016). ApoE ε4 is the isoform that stimulates AD
pathology the most being the greatest genetic risk factor for AD since people with this genetic
trait have an increase level of a particular cholesterol transport and thus have a greater risk of
late-onset Alzheimer's (Di Paolo and Kim 2011, Devassy et al. 2016). While 40–65% of people
with AD patients have at least one copy of the ε4 allele, APOE4 is not a surefire determinant of
the disease despite it being the largest predisposing genetic risk factor (Ryan 2013). About one
third of those with AD negative for the APOE4 allele and some APOE4 homozygotes (two
identical alleles) never develop (Ryan 2013). People who are homozygotic for ε4 alleles,
however, have up to 20 times the risk of developing AD (Ryan 2013). ApoE ε4 is a transporter
with a high affinity for LDL cholesterol which causes the accumulation of more ß-amyloid
peptides (Devassy et al. 2016). The ApoE ε4 genotype strongly affects the deposition of ßamyloid into amyloid plaques (Liu et al. 2013). ApoE ε2 and ε3 have a higher affinity for HDL
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cholesterol and thus have little involvement in AD pathology (Devassy et al. 2016). People
carrying the ε4 ApoE allele have an increased risk of AD in comparison with those carrying the
less dangerous ε2 and ε3 alleles because LDL cholesterol accelerates ß-amyloid formation, and
the ε4 ApoE allele carries LDL to the brain which causes more ß-amyloid build-up (Liu et al.
2013).
The ε4 ApoE allele also increases the risk for cerebral amyloid angiopathy, and the ε4
ApoE allele impairs the BBB by making it more permeable to ß-amyloid (Liu et al. 2013). The
prevalence of dyslipidemia, or high levels of lipids in the blood, caused by LDL cholesterol
weakens the BBB and is associated with its impairment in AD (Bowman et al. 2012).
Conversely, HDL cholesterol strengthens the integrity of the BBB by removing excess LDL
cholesterol (Bowman et al. 2012). The effects of LDL and HDL cholesterol on the BBB and ßamyloid clearance implicate the role of cholesterol in AD pathogenesis (Di Paolo and Kim 2011,
Bowman et al. 2012).

Western Diet and Neurodegeneration
Risk factors for AD include moderate to severe brain traumas in a person’s history, age,
smoking, hypertension, hypercholesteremia, insulin resistance/diabetes, alcohol abuse, and
obesity (Zvěřová M. 2019, Alzheimer Society of Canada). One of the greatest risk factors for
AD, however, is an unhealthy diet since a bad diet can prime the brain for AD (Zvěřová M.
2019). Not only does an unhealthy diet put one at greater risk for developing AD, but an
unhealthy diet may also hasten the development of cognitive decline in someone that already has
it (Dandona et al. 2007, Hanson et al. 2013). Recent studies have shown that diets high in fat,
sugar, and cholesterol, a staple of the average American diet, rob the brain of substances, such as
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DHA, that help to clear β-amyloid which contributes the buildup of plagues that is a hallmark of
AD (Hanson et. Al 2013). Although oxidative stress is part of the AD disease pathology due to
the increased presence of ß-amyloid, high amounts of LDL cholesterol from diet can trigger
oxidative stress and cause inflammation (Moreira et al. 2012, Moreira et al. 2014, Farnaghi et al.
2017).
An unhealthy diet results in malnourishment meaning that a person’s diet does not
contain the right amount of nutrients. Though people tend to associate malnourishment with
being thin and frail, that is not always the case as malnourishment stems from lack of nutrients
and a lack of a healthy diet, but not necessarily whether a person is thin or obese. Preventing
malnourishment is indispensable for good brain health. Studies have established that a
correlation exists between frailty and AD, but there is also a correlation between malnutrition
and AD (Buchman et al. 2008, Meijers et al. 2014). This is a crucial distinction to make because
AD patients do not always experience weight loss or frailty, but still may not be getting the right
nutrition in their diets making them malnourished. This malnourishment could exacerbate the
production of ß-amyloid if the person is eating the wrong type of diet, such as one high in fat or
sugar (Hanson et. Al 2013). ß-amyloid plaques accumulating leads to neurodegeneration in terms
the loss of connections between neurons and cell death (Kim et al 2013).
It’s no secret that the western diet that is a primary part of many people’s lives is far from
healthy. The western diet refers to the standard American diet that is characterized by large
intakes of LDL cholesterol, sugar, high-fructose corn syrup, red meat, processed and prepackaged foods, fried foods, fast food, and high fat dairy products (Guerin et. al 2005). The
average American diet is ill-proportioned in that people tend to overeat, and meals often lacks
the correct amounts of unprocessed fruits and vegetables, whole grains, fish, and poultry needed
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to sustain a healthy lifestyle (Guerin et. al 2005). In fact, an unhealthy diet directly ties in with
some of the leading causes of death in the U.S such as cardiovascular disease and diabetes
(Guerin et. al 2005). Typical American diets far exceed the recommended daily intake of
calories, and many foods contain a superfluous amount of LDL cholesterol, sugar, sodium, fat,
and processed chemicals. Unhealthy dietary habits that lead to hypertension, insulin resistance,
inflammatory processes, metabolic syndrome, midlife obesity, and excessive free radicals also
increase the risk of AD (Zvěřová et al. 2019). Vascular risk factors and vascular disease closely
correlate with the neurodegenerative aspect of AD in that an unhealthy diet impacts the vascular
system which disrupts the BBB causing blood plasma containing ß-amyloid to enter the brain
and accelerate the formation of plaques (Zipser et al. 2007).

Need for More AD Treatment Options Using Dietary Substances
Exploring dietary substances as potential tools to improve the AD prognosis is an
important endeavor to undertake because according to the CDC, AD is in the top ten list of most
expensive chronic diseases to treat in the U.S (Health and Economic Costs of Chronic Disease).
In 2018, the estimated cost of Dementia and Alzheimer’s care in the U.S was $277 billion dollars
and by 2040, the costs of treating AD is projected rise between $379 billion and $500 billion
annually (Alzheimer’s Association, Health and Economic Costs of Chronic Disease). Not only
have the healthcare costs of managing the disease gone up, but the number of deaths caused by it
have increased exponentially in the last decade. Finding alternative treatment options that are
cost effective and efficient in slowing the progression of the disease is no easy task, but one that
must be undertaken in order to eventually improve the quality of life for those living with AD
and their caretakers who also share in the heartache and financial burden.
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Changing one’s diet and eating healthy to slow the progression of AD or dementia or try
to prevent it all together (within the limits of genetics) is one of the easier and more costeffective ways of helping and protecting oneself. Though a change in diet is more easily
accessible and less costly than medications, this is in no way to discourage the use of medication
to treat AD. Diet alone cannot replace AD treatment with medication, but eating healthier goes a
long for promoting brain health, and slowing the progression of AD. Diet can not only improve
one’s overall health and cognition, but many dietary substances, such as DHA and curcumin, can
combat the effects of ß-amyloid and the other slew of factors that hasten neurodegeneration in
AD.

Docosahexaenoic Omega-3 Fatty Acids and Neural Development
Neurodegeneration is impacted when one’s diet is deficient of Docosahexaenoic acid
(DHA) (Lukiw et al. 2005). DHA is the omega-3 polyunsaturated fatty acid (O3PUFA) most
abundantly found in the brain tissues accounting for one third of the polyunsaturated fatty acids
in the brain (Wu et al. 2015). DHA is one of the main structural component of the brain, and is
essential for the development of the brain itself as well as also helping to form the retina and the
liver (Anderson et al. 1990). The dietary intake of DHA supports properties of the cell
membranes found in gray matter (Wu et al. 2015). DHA is transported from blood in the
circulatory system, and it crosses the BBB to get to the brain (Zhao and Zlokovic 2014).
DHA is associated with cognitive decline as the amount of brain DHA is decreased in those with
AD (Moriguchi and Salem 2003, Lukiw et al. 2005). This is because DHA attenuates, or reduces,
the secretion of ß-amyloid thus participating in the pathophysiology of AD (Lukiw et al. 2005).
DHA not only reduces the ß-amyloid burden but also alleviates the other aspects of the AD
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induced by excessive ß-amyloid. DHA also reduces neuronal degeneration and rescues learning
ability as experimentally demonstrated through rodent models with an accumulation of ßamyloid in their brains (Lukiw et al. 2005). DHA is typically obtained through dietary means,
particularly with the consumption of fish and fish oils which are rich in DHA omega-3
polyunsaturated acids. DHA deficiency can be mediated by a healthy dietary intake of foods
containing DHA O3PUFAs (Lukiw et al. 2005). Studies have showed that dietary DHA is
efficient in increasing brain DHA content and improving brain function which has implications
for the prevention and treatment of diseases like AD that are associated with DHA deficiency
(Sugasini et al. 2017).

Curcumin and Neural Development
Curcumin, a natural substance derived from the turmeric plant, is a powerful antioxidant
that has been found to cross the BBB and clear ß-amyloid from the brain. Curcumin derivatives
are capable of acting as potent ß-amyloid inhibitors, especially with the ß-amyloid 42 peptide.
Curcumin can bind to ß-amyloid itself, and some curcumin derivatives also bind to APP
(Shinzato et al. 2020). The use of curcumin also increases brain DHA and has beneficial effects
on neuroplasticity which is the ability of the brain to form synaptic connections (Wu et. Al
2015). Curcumin not only reduces the ß-amyloid burden but also alleviates the other aspects of
the AD induced by excessive ß-amyloid. Curcumin not only has the capacity to modulate
neuronal death by slowing the rate at which neurons die which aids in improving the AD
prognosis (Wu et. Al 2015). This is especially pertinent given that the highest curry consumption
is in India, and India has the lowest incidence of AD compared to every other country in the
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world (Lim et al. 2001). The prevalence of AD in India between ages 70-79 is 4.4-fold less than
the AD rate of occurrence in the United States (Lim et al. 2001).

Methodology for Composing the Thesis
Although both ß-amyloid and tau are important aspects of the AD pathogenesis, for the
purposes of this literature review, ß-amyloid will be focused on as ß-amyloid accumulation and
deposition can be primarily credited to triggering the cascade of events that lead to the
progression of AD and the neurodegenerative pathology (Syamima et al. 2019). ß-amyloid is
responsible for inducing many of the other pathological hallmarks of AD including tau
hyperphosphorylation and neurofibrillary tangles which is why ß-amyloid clearance will be the
focus. DHA O3PUFAs and Curcumin will not only be compared based on their ability to clear ßamyloid and prevent its aggregation, but will also be evaluated on their abilities to promote DHA
development in the brain, improve cholesterol levels, improve acetylcholine levels in the AD
brain, improve synapses, alleviate inflammation and oxidative stress, preserve the BBB, promote
neurogenesis, improve memory and learning, and prevent cell death. DHA O3PUFAs and
curcumin will be compared as dietary substances that slow the pathology of the AD by clearing
ß-amyloid and decelerating the aforementioned slew of factors that modulate and accelerate the
progression of AD as a result of ß-amyloid accumulation.

Clearing ß-amyloid and preventing ß-amyloid aggregation in AD

DHA O3PUFAs
Dietary DHA has the potential to improve AD prognosis on account of the fact that it has
the ability to clear ß-amyloid and prevent it from aggregating to form plaques.
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β-amyloid plaques are characteristically linked to AD because these sticky plaques disrupt the
connections between neurons. DHA has been found to promote brain-to-blood clearance of βAmyloid which could effectively prevent the progression of Alzheimer’s Disease (Yan et al.
2019). In various AD mice models with an accumulation of ß-amyloid that were fed a DHA-rich
diet and compared to a control group, the hippocampus and cortex of the mice fed the DHA-rich
diet displayed reduced β-amyloid levels and ß-amyloid toxicity (Lim et al. 2005, Lukiw et al.
2005, Yan et al. 2019). DHA also resulted in a decrease of senile amyloid plaques in the
hippocampus (Yan et al. 2019). In a mouse model where the mice are 17-19 months old, DHAenriched diets have been shown to significantly reduce total ß-amyloid in the brain by over 70%
in comparison to low-DHA diets or control diets (Lim et al. 2005). A DHA-enriched diet
resulted in a 40–50% reduction in the deposition of ß-amyloid in the cortex and hippocampus
(Calon et al. 2004, Lim et al. 2005, Hashimoto et al. 2005). This demonstrates the role of DHA
O3PUFAs in reducing the amyloid plaque burden in AD.
DHA also aids in ß-amyloid clearance by acting as a precursor to neuroprotection D1
(NPD1) which is a specific molecule derived from DHA that represses ß-amyloid 42-triggered
activation of inflammatory genes (Lukiw et al. 2005). NPD1 also upregulates the genes that
prevent apoptosis and reduces the neurotoxicity of ß-amyloid 42 (Lukiw et al. 2005). NPD1,
which has DHA as a precursor, has its biosynthesis stimulated by a-secretase of APP which
reduces ß-amyloid in the hippocampus (Lukiw et al. 2005). Soluble APP-α peptide, which is
generated from APP via the α-secretase pathway, decreases the production of ß-amyloid peptides
while supporting neural growth and stronger synaptic effects (Lukiw et al. 2005). DHA aids in
clearing ß-amyloid because a larger presence of DHA means a greater amount of NPD1 that can
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be biosynthesized by the APP-α peptide which acts to attenuate ß-amyloid, reduce its toxicity,
and promote survival of hippocampal and cortical neurons (Lukiw et al. 2005).

Curcumin
Curcumin also has the potential to improve AD prognosis by clearing ß-amyloid and
preventing it from aggregating to form plaques. Curcumin was recently reported to decrease the
attenuation of ß-amyloid in the brain (Hoppe et al. 2013a). The neuroprotective effects of
curcumin have been examined using hippocampal slices of rats exposed to ß-amyloid through
spectral analysis of multi-electrode array (MEA) recordings of spontaneous neuronal activity
(Hoppe et al. 2013a). Studies using hippocampal rat slices have revealed that curcumin reverses
the tendency for ß-amyloid to attenuate prevents cellular death induced by ß-amyloid (Hoppe et
al. 2013a). This demonstrates curcumin’s ability to modulate ß-amyloid-induced neuronal death
(Hoppe et al. 2013a). Curcumin is most effective in clearing ß-amyloid in low doses of curcumin
in mice models rather than in high doses (Lim et al. 2001, Ye and Zhang 2012). It has been
found from comparing a low-dose curcumin diet, high-dose diet, and control diet that the
amyloid plaque burden decreases in the greatest amount with a low-dose curcumin treatment
which inhibits ß-amyloid toxicity and can significantly decrease amyloid plaques 43-50% (Lim
et al. 2001, Ye and Zhang 2012). Curcumin treatment in lowering the ß-amyloid plaque burden
had the greatest impact in the hippocampus and the cortex (Lim et al. 2001). Low-dose curcumin
also increased cell viability and reduced neuronal death (Ye and Zhang 2012).
Curcumin is able to cross the BBB based on its ability to attenuate ß-amyloid and reduce
its toxicity in low doses making a potential candidate for drug development (Ye and Zhang
2012). Curcumin has been found to be effective in clearing ß-amyloid and preventing its
aggregation because it has a larger affinity, or ability to bind, to ß-amyloid compared to other ß-
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amyloid inhibitors and prevent it from clumping together (Shinzato et al. 2020). Curcumin
derivatives are capable of acting as potent ß-amyloid inhibitors, especially with the ß-amyloid42
peptide, not just by binding to ß-amyloid itself but some curcumin derivatives also bind to APP
(Shinzato et al. 2020). The curcumin derivative known as “curcumin XIV”, for example has a
large binding affinity to APP which is the protein responsible for producing ß-amyloid peptides
in the first place through proteolysis (Priller et. Al. 2006, Shinzato et al. 2020). By binding to
APP, curcumin derivative XIV can inhibit the production of ß-amyloid peptides all together by
preventing the protein from cleaving ß-secretase to form ß-amyloid peptides (Shinzato et al.
2020). Curcumin derivatives also promote ß-amyloid clearance by enhancing the uptake of ßamyloid by macrophages (Zhang et al. 2006). People with AD have defects in phagocytosis in
the clearance of ß-amyloid, and treatment of the macrophages with curcumin derivatives increase
the uptake of ß-amyloid by binding to the macrophages thus leading to its clearance (Zhang et al.
2006).
Summary
Both DHA and curcumin cross the BBB and are capable of clearing ß-amyloid from the
brain. Both substances also act to lower the plaque formation in the hippocampal and cortical
regions of the brain. Reducing ß-amyloid by using DHA and curcumin allows other issues
induced by ß-amyloid to be modulated as will be demonstrated in the following sections.

Promoting development of brain DHA in AD

DHA O3PUFAs
DHA is capable of modulating many of the physiological hallmarks of AD induced by ßamyloid. DHA improves cholesterol metabolism in AD by improving HDL cholesterol levels in
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the brain (Ole and Lone 2000, Di Paolo and Kim 2011). The ability of DHA to increase HDL
cholesterol levels is important for slowing the progression of AD because HDL helps to remove
LDL cholesterol from the blood, HDL helps clear ß-amyloid from the brain, and HDL is crucial
for synapse generation (Ole and Lone 2000, Zuliani et al. 2010, Di Paolo and Kim 2011). DHA
also increases ChAT levels and thus acetylcholine levels in the brain that were reduced by ßamyloid (Minami et al. 1997). DHA has been found to improve synapses, promote
synaptogenesis, and alleviate ß-amyloid-induced synaptic toxicity (Lukiw et al. 2005). Using
dietary DHA to improve synaptic function is crucial because synapses are normally enriched
with DHA, and brain DHA is essential to post-synaptic signaling in neural communication as
well as neuroprotection (Calon et al. 2004). DHA reduces oxidative stress and inflammation in
the brain as well. DHA, because it is able to cross the BBB, has been found to strengthen the
structural integrity of the BBB (Yan et al. 2019). DHA has also been found to promote
hippocampal neurogenesis and cell proliferation thus helping to improve the AD prognosis
(Lukiw et al. 2005, Kawakita et al. 2006). Memory and learning ability have also been shown to
be rescued by DHA supplementation (Minami et al. 1997).

Curcumin
Even though curcumin is capable of alleviating ß-amyloid-induced hallmarks of the AD
pathology on its own, curcumin also promotes the development of brain DHA, and DHA
modulates all of these aforementioned factors as well (Wu et al. 2015). Curcumin stimulates
DHA synthesis through its precursor acid, α-linolenic acid, and also raises the levels of the
enzymes FADS2 and elongase 2 which are involved in DHA synthesis in the hippocampus (Wu
et al. 2015). This means that curcumin increases DHA content by increasing enzyme pool
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available to facilitate the conversion of DHA from ALA which is DHA’s precursor (Wu et al.
2015). Curcumin being able to increase brain DHA is important because a large population of
people today thrive on a plant-based or vegan diet and are unable to obtain adequate levels of
DHA through dietary means to support cognitive development. This issue is alleviated with
dietary curcumin because curcumin is plant-based and is capable of enhancing DHA synthesis
thus raising the amount of DHA in the brain which can aid in treating cognitive disorders like
AD (Wu et al. 2015).

Summary
Both dietary DHA and curcumin are capable of increasing DHA levels in the brain.
Dietary DHA has been found to increase brain DHA levels which not only modulates ß-amyloid
clearance and toxicity, but also participates in alleviating other parts of the AD pathophysiology
and prevents apoptosis (Lim et al. 2005, Lukiw et al. 2005). Promoting brain DHA by using
dietary DHA and curcumin is neuroprotective in that it helps to clear ß-amyloid, improve
cholesterol levels, improve acetylcholine levels in the AD brain, improve synapses and alleviate
synaptic toxicity, alleviate inflammation and oxidative stress, preserve the BBB, promote
neurogenesis, preserve memory and learning, and prevent apoptosis. DHA effectively acts to
modulate all of the aforementioned factors induced by ß-amyloid which is why brain DHA
promotion via dietary DHA and curcumin is important.

Regulating HDL and LDL cholesterol
DHA O3PUFAs
Maintaining cholesterol metabolism helps to modulate the production and subsequent
accumulation of ß-amyloid since cholesterol controls the processing of amyloid precursor protein
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and the synaptotoxic signaling of ß-amyloid formation (Hashimoto et al. 2005). DHA O3PUFAs
improve cholesterol metabolism in AD by improving HDL cholesterol levels in the brain (Ole
and Lone 2000, Di Paolo and Kim 2011). The ability of DHA to increase HDL cholesterol levels
is important for slowing the progression of AD because HDL helps to remove LDL cholesterol
from the blood, and HDL clears ß-amyloid (Zuliani et al. 2010, Di Paolo and Kim 2011). HDL
also helps to clear ß-amyloid from the brain, and HDL is crucial for synapse generation (Ole and
Lone 2000, Zuliani et al. 2010, Di Paolo and Kim 2011). LDL cholesterol leads to ß-amyloid
accumulation by inducing the processing of APP and the cleavage of ß-amyloid (Yao and
Papadopoulos 2002, Di Paolo and Kim 2011). Although DHA does not decrease LDL
cholesterol directly, it increases HDL, and HDL acts to lower LDL levels (Ole and Lone 2000,
Zuliani et al. 2010, Di Paolo and Kim 2011).

Curcumin
Curcumin also improves cholesterol metabolism in AD by improving HDL cholesterol
levels in the brain which helps to clear LDL cholesterol (Arafa et al. 2005, Santoso et al. 2008).
Curcumin is most effective in modulating cholesterol metabolism in low doses because curcumin
has poor water solubility, and curcumin can get to the brain faster in low doses (Santoso et al.
2008). In addition to raising HDL cholesterol levels, administration of curcumin in low-doses
reduced total LDL cholesterol levels in the brain directly (Santoso et al. 2008).

Summary
Both DHA and curcumin improve HDL cholesterol levels in the brain which helps to
remove LDL cholesterol from the blood, and clear ß-amyloid. DHA does not lower LDL
cholesterol directly, but promotes an increase in HDL cholesterol so that LDL cholesterol can be
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lowered. Curcumin, on the other hand lowers LDL cholesterol directly in addition to also
promoting increased levels of HDL cholesterol.

Improving Acetylcholine levels
DHA O3PUFAs
Cholinergic dysfunction is a hallmark of AD pathology induced by ß-amyloid
accumulation in that ß-amyloid aggregation reduces ChAT levels and thus acetylcholine levels in
the hippocampus (Minami et al. 1997, Hashimoto et al. 2005). DHA O3PUFAs have been found
to increase acetylcholine levels (Minami et al. 1997, Machová et al. 2006). DHA treatment
stimulates ChAT activity in the brain thus increasing acetylcholine levels (Machová et al. 2006).
DHA has also been found to prevent the degeneration of the cholinergic system in rats infused
with ß-amyloid by preventing ChAT levels from decreasing (Machová et al. 2006, Belkouch et
al. 2016). Despite the fact that DHA improves ChAT levels and acetylcholine levels in the brain,
DHA does not affect AChE activity at all (Aïd et al. 2003, Shahdat et al. 2004).

Curcumin
Curcumin has also been found to increase acetylcholine levels in the brain by increasing
ChAT levels in the hippocampus (Ishrat et al. 2009). ChAT dysfunction, which causes the
amount of acetylcholine produced in the hippocampus to be reduced, was reversed and elevated
by curcumin treatment (Liu et al. 2016). Curcumin has also been found to be neuroprotective to
cholinergic neurons in mice models (Liu et al. 2016). Curcumin derivatives have also been found
to inhibit the activity of AChE in the hippocampus and frontal cortex, the enzyme that cleaves
acetylcholine (Ahmed et al. 2009, Akinyemi et al. 2017). Curcumin inhibits AChE activity by
crossing the BBB and inhibiting the enzyme in order to provide more time for acetylcholine to
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stimulate postsynaptic receptors (Ahmed et al. 2009, Akinyemi et al. 2017). Curcumin
derivatives acting as an AChE inhibitor make it a potential candidate for an AD drug.

Summary
Both DHA and curcumin increase ChAT activity as well as acetylcholine levels which
helps to strengthen and improve synaptic function as well as counteract ß-amyloid-induced
cholinergic dysfunction. Dietary DHA has no effect on decreasing AChE activity. Unlike DHA,
curcumin acts to decrease AChE activity.

Improving synapses between neurons in AD/alleviating synaptic toxicity

One of the issues characteristic of the AD pathogenesis is gradual synaptic dysfunction
that occurs as a result of ß-amyloid accumulation (Kokawa et al. 2015). ß-amyloid is a modulator
of synaptic plasticity because ß-amyloid disrupts communication between neurons (Kokawa et
al. 2015). A synapse is the junction between two neurons through which neurotransmitters
diffuse across to communicate with other neurons thereby making the synapse the physical
location of neural communication.

DHA O3PUFAs
DHA has been found to strengthen synapses, promote synaptogenesis, and alleviate ßamyloid-induced synaptic toxicity (Lukiw et al. 2005). One of the ways in which DHA promotes
synapse growth and formation is through NPD1, whose precursor is DHA, being biosynthesized
by the sAPPα peptide from APP via the α-secretase pathway (Lukiw et al. 2005). This is because
sAPPα elicits the growth and formation of synapses (Lukiw et al. 2005). Loss of synapses and
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synaptoxicity largely stems from ß-amyloid accumulation which is why DHA helping to clear ßamyloid subsequently improves synaptic dysfunction as well (Lukiw et al. 2005, Kokawa et al.
2015). Using dietary DHA to improve synaptic function is crucial because synapses are normally
enriched with DHA, and brain DHA is essential to post-synaptic signaling in neural
communication as well as neuroprotection (Calon et al. 2004). Repletion of DHA in an AD brain
with low levels of DHA helps to prevent synaptic loss (Calon et al. 2004). DHA also promoted
the expression of synaptic proteins synapsin I and CaMKII to improve synapses (Wu et al.
2008).
DHA also improved synapses through modulating cholesterol levels. HDL cholesterol
not only aids in ß-amyloid clearance, but is also crucial for synapse generation, maturation, and
symaptic plasticity in that it increases the number of synaptic vesicles which have high
cholesterol levels (Mauch et al. 2001, Zuliani et al. 2010, McGrowder et al. 2011). Synapses are
improved by DHA in that it acts to increase of acetylcholine levels which are also crucial
modulators of synapses, because cholinergic disruption is increased in patients with AD (Minami
et al. 1997). DHA’s ability to preserve synaptic integrity is important to functions involving
learning and memory in AD (Minami et al. 1997, Calon et al. 2004, Lukiw et al. 2005). DHA
also improves long-term potentiation in the brain which is a persistent strengthening of synapses
based on patterns of activity (Fujita et al. 2001, Hashimoto et al. 2005, Cook et al. 2006). DHA is
crucial for the initiation of long-term potentiation, and DHA therefore, enhances synapse
strength (Fujita et al. 2001, Hashimoto et al. 2005).

37
Curcumin
Curcumin has also been found to strengthen synapses, promote synaptogenesis, and
alleviate ß-amyloid-induced synaptic toxicity (Hoppe et al. 2013a). Curcumin counteracts
synaptic dysfunction in the hippocampus through ß-amyloid clearance since ß-amyloid is
synaptoxic and causes neuronal circuits and synapses to dismantle over time (Hoppe et al.
2013a). Curcumin also prevented synaptic dysfunction by regulating the synaptic proteins
synapsin I and CaMKII thus showing the neuroprotective and synaptoprotective role of curcumin
(Ye and Zhang 2012, Hoppe et al. 2013a, Hoppe et al. 2013b). Both CaMKII and synapsin I are
the key proteins involved in presynaptic neurotransmitter release, and both of these synaptic
proteins and are crucial to maintaining synaptic plasticity which is the ability of synapses to
strengthen over time (Ye and Zhang 2012, Hoppe et al. 2013a, Hoppe et al. 2013b). Curcumin
promoted synaptogenesis by preventing the ß-amyloid-induced inactivation of CaMKII and
synapsin I which improved synapses in the hippocampus (Ye and Zhang 2012, Hoppe et al.
2013a, Hoppe et al. 2013b). Curcumin also increased number of synapses in the brain, and
promoted the ultrastructure or structural integrity of the synapses (Chen et al. 2018).
Curcumin improves synapses through modulating cholesterol levels as well. HDL
cholesterol not only aids in ß-amyloid clearance, but is also crucial for synapse generation,
maturation, and symaptic plasticity in that it increases the number of synaptic vesicles which
have high cholesterol levels (Arafa et al. 2005, Santoso et al. 2008). Synapses are improved by
curcumin in that it acts to increase of acetylcholine levels which are also crucial modulators of
synapses, because cholinergic disruption is increased in patients with AD (Arafa et al. 2005,
Santoso et al. 2008). Unlike DHA, curcumin also modulates the over activity of AChE which
allows acetylcholine to remain in the synapse lone enough to be effective in communicating to a
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post-synaptic neuron AD (Arafa et al. 2005, Santoso et al. 2008). Curcumin derivatives also
rescue long-term potentiation and thus modulate synapses by enhancing synapse strength
(Ahmed et al. 2011).

Summary
DHA and curcumin have both been found to strengthen synapses, promote
synaptogenesis, promote long-term potentiation, and alleviate ß-amyloid-induced synaptic
toxicity. Both are capable of doing so by clearing ß-amyloid, increasing the expression of
synaptic proteins, CaMKII and synapsin I, and by modulating cholesterol levels. DHA, in
particular, is adept at strengthening synapses through NPD1, a molecule for which DHA is the
precursor. Curcumin, in particular, is adept at strengthening synapses by inhibiting AChE
activity.

Anti-inflammation/antioxidant properties
DHA O3PUFAs
Oxidative stress is one of the pathological hallmarks of AD induced by ß-amyloid
aggregation. DHA has been found to exhibit neuroprotective effects with its anti-inflammatory,
anti-oxidative, anti-apoptotic properties (Lukiw et al. 2005, Van et al. 2019). NPD1, the
substance that had DHA as its precursor, regulates anti-inflammatory, and anti-apoptotic geneexpression that promotes the survival of neurons (Lukiw et al. 2005). DHA has also been found
to reduce damage occurring as a result of ß-amyloid-induced oxidative stress (Hashimoto et al.
2005, Lim et al. 2005, Lukiw et al. 2005). The oxidation of lipids is known as lipid peroxidation,
and it is the degradation of lipids that results from the destructive process of oxidation (Pham-
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Huy et al. 2008). DHA was found to suppress the increases of lipid peroxide and reactive oxygen
species in the cerebral cortex and the hippocampus of in rats infused with ß-amyloid
demonstrating that DHA increases anti-oxidative defenses (Hashimoto et al. 2005).

Curcumin
Curcumin has been found to exhibit neuroprotective effects with its anti-inflammatory,
anti-oxidative, anti-apoptotic properties (Lim et al. 2001, Ishrat et al. 2009, Xu et al. 2009, Wu et
al. 2015). Curcumin was found to resist lipid peroxidation which is important because many
structures in the brain, including the cell membranes of cells, are composed of lipids and
preventing their ß-amyloid-induced peroxidation is crucial to neurons being able to maintain
their structure (Ishrat et al. 2009). Curcumin supplementation also increased the activity of antioxidative enzymes in both the hippocampus and the cerebral cortex (Ishrat et al. 2009). In this
way, curcumin enhanced the anti-oxidant defenses in the brain (Lim et al. 2001, Ishrat et al.
2009, Xu et al. 2009). Curcumin also acts to inhibit neuroinflammation by promoting the activity
of the peroxisome proliferator-activated acceptor (PPARγ) (Liu et al. 2016). PPARγ is a target of
curcumin that acts to alleviate neuroinflammation, and activating this receptor modulates the
inflammatory response to oxidation (Liu et al. 2016). Nano-curcumin, a curcumin derivative, has
also been found to relieve inflammation and oxidative stress by reducing the activation of
microglia 1 (M1) which a mediator of pro-inflammatory responses (Wang et al. 2019).
Summary
Both dietary DHA and curcumin reduce inflammation and oxidative stress induced by ßamyloid. Both dietary substances also prevent lipid peroxidation to protect the structures of cell
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membranes. DHA does so through NPD1, a molecule with DHA as a precursor. Curcumin does
so through promoting PPARγ activity and by reducing M1 activation.

Preserving the BBB and enhancing LRP-1 levels in AD
DHA O3PUFAs
Vascular damage plays a role in the pathogenesis of AD since the loss of structural
integrity of the BBB in AD allows blood plasma containing ß-amyloid to enter the brain
(Hooijmans et al. 2007, Zipser et. al 2007). The BBB becomes compromised when inflammation
from oxidative stress weakens the BBB by increasing its permeability to ß-amyloid (Magaki et
al. 2018). DHA supplementation modulates the integrity of the BBB (Hooijmans et al. 2007).
DHA, because it is able to cross the BBB, has been found to strengthen the structural integrity of
the BBB (Yan et al. 2019). DHA promotes BBB clearance of β-amyloid, and the removal of ßamyloid from the brain promotes the strengthening of the BBB (Hong et al. 2015, Pan et al.
2018, Yan et al. 2019). This is because ß-amyloid adheres to astrocytes (glial cells that support
the neuron and regulates synapses) when it enters the brain thus weakening the glial cells that
support the neurons in the BBB (Hooijmans et al. 2007, Zipser et. al 2007). Clearing ß-amyloid
from the brain and alleviating the amyloid plaque burden, consequently, preserves the BBB (Lim
et al. 2005, Yan et al. 2019). The BBB is dependent on LRP-1 to clear β-amyloid from the brain,
and DHA has been found to enhance the production of LRP-1 receptors in mice models meaning
that more β-amyloid can be removed from the BBB (Yan et al. 2019).
Dietary DHA also protects against BBB being compromised by enhancing the expression
of fatty acid-binding protein 5 (FABP5) (Pan et al. 2018). DHA’s ability to travel across the
BBB is modulated by FABP5, and low brain DHA is associated with low BBB expression of
FABP5 (Pan et al. 2018). Supplementation with dietary DHA enhances the upregulation of
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FABP5 which facilitates the transport of DHA across the BBB (Pan et al. 2018). Enhancing the
transport of DHA across the BBB strengthens the integrity of the BBB because DHA helps to
clear that ß-amyloid (Yan et al. 2019).
DHA modulates the integrity of the BBB by increasing HDL cholesterol levels which act
to decrease ß-amyloid production and strengthen the BBB (Arafa et al. 2005, Hooijmans et al.
2007, Santoso et al. 2008). The excessive intake of LDL cholesterol impairs the vasculature of
the BBB causing vulnerable areas of the brain to experience hypoperfusion, or reduced blood
flow, which leads to ß-amyloid accumulation, and CAA (Hooijmans et al. 2007). DHA also
increased regional cerebral blood flow to the brain thus improving blood circulation in the brain
(Hooijmans et al. 2007). DHA’s ability to cross the BBB makes it a potential candidate for drug
development (Yan et al. 2019).

Curcumin
Curcumin promotes BBB clearance of β-amyloid as well (Jiang et al. 2007). Curcumin is
able to cross the BBB based on its ability to attenuate ß-amyloid and reduce its toxicity in low
doses (Ye and Zhang 2012). The removal of ß-amyloid from the brain also promotes the
strengthening of the BBB (Ye and Zhang 2012). Curcumin derivatives at low concentrations can
preserve the BBB by alleviating ß-amyloid toxicity as well as the amyloid plaques burden (Lim
et al. 2019). The neuroprotective effect of curcumin lies within its high affinity for ß-amyloid
which is why curcumin binding to ß-amyloid not only decreases the plaque burden but also helps
to preserve the BBB (Lim et al. 2019, Shinzato et al. 2020). Insofar as enhancing the structural
integrity of the BBB goes, curcumin has not been found to directly enhance LRP-1 levels in the
BBB.
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Curcumin also regulates the permeability of the BBB through curcumin derivatives
known as “nano-curcumin” that protect the BBB by reducing M1 microglial activation (Jiang et
al. 2007, Wang et al. 2019). M1 is a protein that mediates pro-inflammatory responses in the
brain (Wang et al. 2019). Nano-curcumin protects the BBB by reducing oxidative stress and the
resulting inflammation since inflammation weakens the structural integrity of the BBB by
making it more permeable to toxic substances (Wang et al. 2019). Curcumin is also capable of
protecting the ultrastructure of the BBB and reducing edema, or swelling caused by
inflammation (Yu et al. 2012). Curcumin further modulates the strength of the BBB by
increasing HDL cholesterol levels which act to decrease ß-amyloid production (Arafa et al. 2005,
Hooijmans et al. 2007, Santoso et al. 2008). Decreasing ß-amyloid production means that there is
less ß-amyloid that can adhere to astrocytes and weaken the BBB. Since curcumin is able to
cross the BBB, it is a potential candidate for drug development (Ye and Zhang 2012, Wang et al.
2019, Shinzato et al. 2020).

Summary
DHA and curcumin can both cross the BBB and are capable of strengthening the BBB
that was compromised from ß-amyloid making them good candidates for drug development.
Both dietary substances also help modulate the BBB by increasing HDL cholesterol levels which
acts to decrease ß-amyloid. Decreasing ß-amyloid production means that there is less ß-amyloid
that can adhere to astrocytes and weaken the BBB. DHA enhances the production of LRP-1
receptors thus enhancing ß-amyloid clearance and making it so that more DHA can cross the
BBB. Conversely, curcumin has not been found to directly enhance LRP-1 levels in the brain.
Aside from clearing ß-amyloid, DHA protects against disruption by enhancing FABP5
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expression. Curcumin protects the BBB by reducing M1 activation and by reducing edema
caused by inflammation. Although curcumin can cross the BBB just like dietary DHA, it is only
effective in low doses on account of curcumin’s low water solubility whereas dietary DHA can
be effective in high doses as well as low.

Neurogenesis
In AD, the neurological process of neurogenesis, particularly in the hippocampus and
cortex, is reduced (Scopa et al. 2020). Neurogenesis is yet another physiological process
inhibited by the attenuation of ß-amyloid peptides in AD (Haughey et al. 2002). Neurogenesis is
the process by which neurons, the cells in the brain, are produced from neural stem cells (Gilbert
et al. 2014). Contrary to popular belief, the process of the brain forming new neurons through
neurogenesis is something that occurs throughout the adult life. Neurons, unlike somatic cells, do
not divide through mitosis to form new neurons which is why they are formed from neural stem
cells (Gilbert et al. 2014). Adult neurogenesis also occurs at a slower rate with low efficiency,
compared to when neurogenesis occurs at the beginning of human life in embryos (Gilbert et al.
2014, Van et al. 2019).
In the average human adult, about 700 new neurons are added to the hippocampus each
day (Spalding et al. 2013). The newly formed neurons, however, correspond to a high turnover
rate, and the rate of neurogenesis declines with age as well (Spalding et al. 2013, Van et al.
2019). Neurogenesis in adults primarily occurs in the olfactory bulb and in the dentate gyrus of
the hippocampus which is the region heavily involved in learning and memory (Alvarez-Buylla
and Lim 2004, Kawakita et al. 2006). Neuronal differentiation is the process by which cells
become specialized for a particular function and mature (Gilbert et al. 2014). Neural stems cells
are capable of differentiating into either neurons or glial cells (the non-neuronal cells that support
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and protect neurons) which is called fate-decision (Gilbert et al. 2014). Fate-decision is what the
cells are determined to become before they differentiate (Gilbert et al. 2014). Promoting
neurogenesis is important because ß-amyloid and the other ß-amyloid-induced factors that
progress AD cause neurodegeneration and cell death which shrinks the AD brain. Neurogenesis
helps to replace the neurons that have died off, and increasing the number of neurons also
correlates with better cognitive performance (He et al. 2009, Dong et al. 2012).

DHA O3PUFAs
DHA has been found to promote hippocampal neurogenesis and cell proliferation thus
helping to improve the AD prognosis (Lukiw et al. 2005, Kawakita et al. 2006). NPD1, which
has DHA as a precursor, has its biosynthesis stimulated by a-secretase of APP which reduces ßamyloid in the hippocampus (Lukiw et al. 2005). Soluble APP-α peptide (sAPPα) promotes
neuritogenesis and long-term survival of hippocampal and cortical neurons (Lukiw et al. 2005,
Kawakita et al. 2006). Neuritogenesis is a type of neurogenesis and is the process of forming
neurites which develop into the axons and dendrites of a neuron (Lukiw et al. 2005, Kawakita et
al. 2006). NPD1, which is formed from DHA, causes sAPPα to further increase neuritogenesis,
and the development of dendrites and axons is what allows neurons to communicate (Lukiw et
al. 2005, Kawakita et al. 2006).
DHA also increases neurogenesis by promoting the differentiation of neural stem cells
into neurons (Kawakita et al. 2006). DHA plays an important role in the function of neurons and
their development because neural stem cells have been shown to require lipids like DHA for the
initiation of neurogenesis and for the neuronal proliferation making DHA important to the
neurobiology of neural stem cells (Van et al. 2019). Lipidogenesis with DHA, therefore largely
determines neural cell differentiation (Van et al. 2019). DHA promotes neural cell differentiation
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into neurons by promoting cell cycle exit by suppressing apoptosis (Kawakita et al. 2006). DHA
prevents the death of differentiating neural stem cells, and increases the survivability of newborn
neurons (Kawakita et al. 2006). DHA also impacts the fate-decision of neural stem cells into
neurons (Van et al. 2019). The maturation of neurons that have differentiated from neural stems
cells is also promoted by DHA (Kawakita et al. 2006). Adequate intake of dietary DHA is
important because it reduces the ß-amyloid burden which stops neurogenesis from being
inhibited by the toxic peptides (Haughey et al. 2002, Van et al. 2019).

Curcumin
Curcumin has also been found to promote hippocampal neurogenesis in order to improve
the AD prognosis (Xu et al. 2009, Tiwari et al. 2013). An increased concentration of curcumin
increases the number of dendritic branches in hippocampal neurons (Xu et al. 2009). Curcumin
specifically promoted neurogenesis by targeting endogenous neural stem cells to modulate neural
differentiation and neurogenesis (Tiwari et al. 2013). Curcumin induces the proliferation of
neural stem cells in the hippocampal and cortical regions by altering mRNA transcription in
genes, and promotes neuronal differentiation in mice models (Dong et al. 2012, Tiwari et al.
2013).
The expression of genes related to neuronal growth were promoted by curcumin
treatment showing that curcumin reverses impaired hippocampal neurogenesis through altering
gene expression (Dong et al. 2012). The expression of the NeuroD1 gene, a gene that promotes
neurogenesis and the survival of neural stem cells, was enhanced in the cortex of curcumintreated rats (Dong et al. 2012). The NeuroD6 gene, which regulates neuronal differentiation and
energy metabolism, promoted neuronal survival and the expression of this gene was also
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enhanced by curcumin treatment (Dong et al. 2012). The expression of the Wnt2 gene, which is
involved in dendritic arborization (branching) and growth in adult neurogenesis, was upregulated
in the hippocampus as a result of curcumin treatment (Dong et al. 2012). The Tiam1 gene, a gene
vital to neurite outgrowth that modulates neuronal morphology (shape), was enhanced in the
cortex from curcumin treatment (Dong et al. 2012). Curcumin also increases the expression of
genes involved in neuronal differentiation such as neurogenin, neuro D1, neuregulin, neuroligin,
and Stat3 (Tiwari et al. 2013).
The ability of curcumin to improve neurogenesis and cell proliferation primarily lies in
curcumin’s ability to up-regulate or enhance the expression of genes in the brain associated with
neuronal development (Dong et al. 2012, Tiwari et al. 2013). Another important feature about the
gene profiles of rats with prolonged curcumin treatment is that the genes that were previously
indicated to participate in the neurodegenerative processes of AD represented a large percentage
of the total number of genes altered by curcumin (Dong et al. 2012). Prolonged curcumin
treatment has the potential to act as a mechanistic mediator for governing the adult neurogenesis
and cell proliferation in the cortex and hippocampus by enhancing gene expression and
modulating neuronal networks that coordinate neurogenesis (Dong et al. 2012, Tiwari et al.
2013).
Summary
DHA and curcumin both promote hippocampal neurogenesis and cell proliferation thus
helping to improve the AD prognosis. Both DHA and curcumin also promote neuriteogenesis,
neural stem cell differentiation, and neuronal fate decision. DHA promotes neurogenesis and cell
proliferation through NPD1 interacting with sAPPα, promoting the maturation of neurons, and
by promoting the differentiation of neural stem cells. Curcumin promotes neurogenesis and cell
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proliferation by increasing the number of dendritic branches, targeting endogenous neural stem
cells to modulate neural differentiation, and by promoting the expression of genes that promote
neurogenesis.

Improving memory and learning
DHA O3PUFAs
Deficits in short-term memory and learning ability are a characteristic part of AD largely
caused by synaptic dysfunction and amyloid plaques. Dietary DHA has been found to benefit
cognition and learning, and has been found to alleviate some deficits in memory (Minami et al.
1997, Gamoh et al. 1999, Moriguci and salem 2003, Lim et al. 2005). It was found using a mice
model that feeding multiple generations of mice diets lacking DHA O3PUFAs limits their
learning ability and spatial task performance, but learning was restored when their diets were
switched to ones that were supplemented with DHA (Moriguci and salem 2003). It was also
found that animals given a DHA-rich diet since birth or weaning were able to achieve almost the
same level of brain DHA and spatial task performance as the same animals that were maintained
on a DHA-rich diet for three generations (Moriguci and salem 2003). This demonstrates that
some loss of brain function associated with low DHA levels can be reversed through a DHA-rich
diet (Moriguci and salem 2003).
DHA administration for 12 weeks was also found help modulate reference and working
memory errors as well as spatial cognition in rats infused with ß-amyloid as results from the
Morris water maze navigation task demonstrated (Gamoh et al. 1999, Hashimoto et al. 2005).
Reference memory involves using information that remains constant over time whereas working
memory involves holding on to information that is only pertinent within a short period of time.
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Following the administration of a DHA-rich diet, the number of working memory errors in
young rats decreased (Gamoh et al. 1999). DHA administration improved long-term memory in
both young and old rats (Gamoh et al. 1999, Hashimoto et al. 2005). DHA administration also
increased both the cortical and the hippocampal levels of DHA which suggested the
improvement of impaired spatial cognition learning ability (Hashimoto et al. 2005). Long-term
potentiation, the strengthening of synapses based on patterns of activity, was also improved by
DHA supplementation (Minami et al. 1997, Hashimoto et al. 2005). DHA is crucial for longterm potentiation because it DHA not only reverses impairment in long-term potentiation, but
DHA triggers the expression of long-term potentiation (Minami et al. 1997, Hashimoto et al.
2005).
Cholinergic dysfunction in AD causes more ß-amyloid peptides to be produced, and is
partially responsible for impaired learning ability (Minami et al. 1997). DHA rescues learning
ability and improves passive avoidance performance by ameliorating the reduction in
acetylcholine levels in the brain (Minami et al. 1997). Spatial learning performance also
increased with enhanced DHA-induced neurogenesis (He et al. 2009). This is because growth in
terms of neuronal proliferation, or the number of neurons, correlates with improved spatial
memory (He et al. 2009). DHA’s ability to decrease oxidative stress also improved short-term
memory in terms of immediate recall (Mazereeuw et al. 2017).

Curcumin
Curcumin has also been found to benefit cognition and learning, and has been found to
alleviate some deficits in memory (Hoppe et al. 2013b). Curcumin treatment was found to
improve both short-term and long-term recognition memory in rat models indicating that
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curcumin enhanced the animals’ ability to distinguish between familiar and new one objects
(Hoppe et al. 2013b). Cognitive performance in rat models in the passive avoidance task and
spatial task performance when the Morris water maze navigation task was used was improved
with curcumin treatment (Ishrat et al. 2009, Xu et al. 2009). The passive avoidance task
measures the ability for an organism to avoid an area or path where an adverse stimulus was
delivered, and the spatial task measures the ability to perceive spatial relationships in respect to
body orientation amidst environmental distractions. Specifically, curcumin reversed impaired
spatial memory in the the Morris water maze navigation task as evidenced by decreased escape
latencies (Xu et al. 2009, Liu et al. 2016).
Learning and memory impairments in the ß-amyloid infused rat model of the AD
phenotype can also be rescued by curcumin’s ability to induce neurogenesis and cell
proliferation (Dong et al. 2012, Tiwari et al. 2013). An increase in the number of neurons from
curcumin-induced hippocampal proliferation correlates with improved spatial memory which
shows the memory-enhancing ability of curcumin in the promotion of neurogenesis (Dong et al.
2012). For this reason, spatial memory was improved significantly after 12 weeks of curcumin
treatment (Dong et al. 2012). Curcumin’s ability to alleviate oxidative stress also improves
spatial memory deficits (Ishrat et al. 2009, Dong et al. 2012). Curcumin derivatives also rescue
long-term potentiation and thus modulate synapses by enhancing synapse strength through longterm potentiation (Ahmed et al. 2011).
Curcumin supplementation also restored ChAT activity and promoted cholinergic
neuronal function in the hippocampus, and this restoration ameliorated the deficits in learning
and memory (Ahmed et al. 2009, Ishrat et al. 2009, Liu et al. 2016). This is important because
cholinergic neurons play a crucial role in memory function, and cholinergic dysfunction
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underlies most of the short-term memory loss observed in the AD disease pathology (Ahmed et
al. 2009, Liu et al. 2016).

Summary
Both dietary DHA and curcumin have been found to improve memory and learning.
DHA-induced neurogenesis and curcumin-induced neurogenesis both correlated with improved
spatial memory. Both substances improved short as well as long-term memory, working
memory, reference memory, and long-term potentiation. Both DHA and curcumin also improved
spatial memory deficits by promoting cholinergic function since cholinergic neurons play a
crucial role in memory and underlie most of the short-term memory loss in AD.

Human trials of these Dietary Substances

Many trials and experiments testing the effectiveness of dietary substances in improving
the AD prognosis use mice or rat models to demonstrate findings in vivo. Mice and rat models
provide invaluable insight about the effect of dietary substances on brain areas, since mice share
over 90% of DNA and genes with humans and have the same areas of the brain (Chinwalla et al.
2002). They are also useful laboratory models because experiments are able to be done on them
that may not be feasible or ethical in humans. Despite the fact that there are many benefits to
using animal models, and despite the fact that discoveries about the impact of dietary substances
on the brain are comparable to the likely effect on human brains, it is still important to examine
studies that show the impact of these substances on humans nevertheless.
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DHA O3PUFAs

In the Levi et al. 2014 study, 33 patients were examined with 18 receiving the DHA
supplement and 15 receiving placebo in a double‐blind, placebo‐controlled randomized study
(Levi et al. 2014). At 6 months, the DHA supplement group showed significant increases in
DHA levels in the cerebrospinal fluid whereas no changes were observed in the placebo group
(Levi et al. 2014). Levels of DHA in the cerebrospinal fluid were correlated with prolonged
DHA oral supplementation suggesting the transfer of DHA across the BBB (Levi et al. 2014).
The transfer of DHA across the BBB, therefore, improved after oral dietary supplementation
with DHA as evidenced by the profile of the cerebrospinal fluid (Levi et al. 2014). These
findings are consistent with experiments done in mice models showing that DHA treatment
reduces ß-amyloid and improves AD-related deficits (Levi et al. 2014). Increased DHA content
is associated with improved cognition and a decreased risk of cognitive loss in normal aging
largely because of its ability to reduce ß-amyloid in the brain and improve synaptic function
(Levi et al. 2014).

Another study done by Morris et al. 2003 followed a random sample of a geographically
defined community from 1993 to 2000 with participants being followed up for 3.9 years on
average for the development of AD (Morris et al. 2003). The study was comprised of 815 people
total aged 65-94 years old who were unaffected by AD and completed a dietary questionnaire 2.3
years prior to clinical evaluation for AD through neurological examination via 4 cognitive tests
in a 90-minute interview (Morris et al. 2003). A total of 131 participants developed AD, and it
was found that participants who consumed fish as a source of DHA had a 60% less risk of AD
compared with those that never or seldom ate fish (Morris et al. 2003). This demonstrates that
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dietary intake of DHA was associated with a lower risk of AD which aligns with similar studies
done on mice models (Morris et al. 2003). These findings are significant because it provides the
epidemiologic evidence supporting the link dietary DHA and cognitive performance in human
subjects (Morris et al. 2003).

Curcumin
In the Zhang et al. 2006 study, the macrophages of 6 patients were treated in vitro with
curcumin derivatives so that ß-amyloid uptake using fluorescence and confocal microscopy
could be examined and compared to 3 controls also with AD (Zhang et al. 2006). Following the
treatment of the macrophages with curcumin, 3 out of 6 AD patients showed a significant
decrease in ß-amyloid, whereas there was no change in the controls (Zhang et al. 2006). The
confocal microscopy of the AD macrophages displayed surface binding of curcumin to ßamyloid in untreated macrophages in response to the treatment (Zhang et al. 2006). Curcumin
strongly stimulated uptake of ß-amyloid by macrophages in the participants that the experiment
had an effect on (Zhang et al. 2006). These results are consistent with other literature on mice
models that show curcumin modulating ß-amyloid levels (Zhang et al. 2006). This demonstrates
curcumin’s ability to help stimulate the immune system to clear more ß-amyloid, and makes
sense given curcumin’s ability to cross the BBB (Zhang et al. 2006).
Another study done by Ng et al. 2006 examined the association between curcumin
consumption through curry and cognitive function by following the dietary habits of a random
sample of 1,092 adults aged 60-93 from 2003-2004 based on how often they consumed curry
which is primarily made from curcumin (Ng et al. 2006). The study compared mini-mental state
examination (MMSE) scores of the participants based on three categories of curry consumption:
never or rarely, occasionally, and often or very often (Ng et al. 2006). It was found that
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participants who consumed curry occasionally or often/very often has significantly better MMSE
scores in comparison to subjects that consumed curry never or rarely (Ng et al. 2006). Increased
consumption of curry is associated with better cognitive performance in participants, and curry
consumption also lowered the risk for dementia and AD in the elderly (Ng et al. 2006). Despite
these findings, higher levels of curry consumption were not associated with better cognitive
performance due to the lack of statistical significance in differences between the “occasional”
and “often” curry consumption groups (Ng et al. 2006). This is consistent with experiments done
in mice models showing that low rather than high-dose curcumin treatment reduces ß-amyloid
and improves AD-related deficits (Ng et al. 2006). These findings are significant because it
provides the first epidemiologic evidence supporting the link between curry consumption and
cognitive performance in human subjects (Ng et al. 2006).

Summary
DHA and curcumin were both found to be effective in older adults. DHA and curcumin
both reduced the risk of developing AD. Dietary DHA increased the amount of DHA in
cerebrospinal fluid, and was associated with a reduced risk of AD. Curcumin was found to be
effective in the treatment of AD macrophages in ß-amyloid clearance, and was associated with a
reduced risk of AD. The findings for the effects of DHA and curcumin in humans align with
experiments that tested theses same hypothesis on mice models. These human experiments
exploring the neurological impact of both DHA and curcumin are significant because it provides
epidemiologic evidence supporting the link between diet and cognitive performance in human
subjects.

Conclusion
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Both DHA O3PUFAs and curcumin have both been scientifically proven to be effective
in clearing ß-amyloid and modulating other ß-amyloid induced factors in the AD pathogenesis.
DHA O3PUFAs and Curcumin clear ß-amyloid and have been found to promote DHA
development in the brain, improve cholesterol levels, improve acetylcholine levels in the AD
brain, improve synapses, alleviate inflammation and oxidative stress, preserve the BBB, promote
neurogenesis, improve memory and learning, and prevent cell death.
A poor or a healthy diet not only impacts the body, but also plays a major role in brain
health (Hanson et al. 2013). Typical American diets far exceed the recommended daily intake of
calories, and many foods contain a superfluous amount of LDL cholesterol, sugar, sodium, fat,
and processed chemicals that increase the risk for cognitive decline. With the treatment options
for AD being both limited and expensive, exploring the link between diet and AD is such a
crucial endeavor to undertake in order to slow the progression of the disease. The fundamental
goal of this research was to examine both DHA O3PUFAs and curcumin in order to investigate
their ability to clear ß-amyloid and alleviate aspects of the AD pathology induced by ß-amyloid.
Eating a diet with more of these substances can help in clearing ß-amyloid as well as
mediating the aspects of AD pathology induced by ß-amyloid. While many AD treatments target
one aspect of the disease, AD, as demonstrated by the sections above, is a multi-faceted disease,
the cause of which is not completely understood with many factors being involved. Exploring
dietary substances as viable treatment options is worth looking into because only five FDAapproved drugs are currently used to treat AD, so exploring more treatment options is necessary
(Alzheimer’s Association). A dietary increase in DHA O3PUFAs and curcumin has the potential
to exhibit widespread effects in treating AD without the harmful side-effects of pharmaceutical
drugs which often serve as a “one-size-fits-all” solution to a complex problem. Learning about
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what natural dietary substances increase slow the progression of AD has serious implications for
improving the conditions of the millions of people living with AD in terms of increasing life
expectancy, creating a healthier way of life, and coming closer to eventually finding a cure for
AD.
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